trypsin edta solution  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    Name:
    Trypsin EDTA Solution TE
    Description:
    Gibco Trypsin solutions are made from trypsin powder a mixture of proteases derived from bovine pancreas Due to its digestive strength it is widely used for cell dissociation during routine cell culture passaging and primary tissue dissociation This Gibco Trypsin EDTA solution is formulation as 0 025 trypsin and 0 01 EDTA in Phosphate Buffered Saline PBS We offer a variety of Gibco Trypsin and animal origin free TrypLE cell dissociation products to meet your needs This trypsin is manufactured as follows WithEDTAPhenol RedThe complete formulation is available Product UseFor Research Use Only Not for use in diagnostic procedures cGMP Manufacturing and Quality SystemGibco Trypsin is manufactured at a cGMP compliant facility located in Grand Island New York The facility is registered with the FDA as a medical device manufacturer and is certified to ISO 13485 standards
    Catalog Number:
    R001100
    Price:
    None
    Category:
    Cell Culture Transfection Reagents
    Applications:
    Cell Culture|Corneal Epithelial Cell Culture|Fibroblast Culture|Keratinocyte Culture|Large Vessel Endothelial Cell Culture|Mammalian Cell Culture|Mammary Epithelial Cell Culture|Melanocyte Culture|Microvascular Endothelial Cell Culture|Smooth Muscle Cell Culture|Primary Cell Culture
    Buy from Supplier


    Structured Review

    Thermo Fisher trypsin edta solution
    Gibco Trypsin solutions are made from trypsin powder a mixture of proteases derived from bovine pancreas Due to its digestive strength it is widely used for cell dissociation during routine cell culture passaging and primary tissue dissociation This Gibco Trypsin EDTA solution is formulation as 0 025 trypsin and 0 01 EDTA in Phosphate Buffered Saline PBS We offer a variety of Gibco Trypsin and animal origin free TrypLE cell dissociation products to meet your needs This trypsin is manufactured as follows WithEDTAPhenol RedThe complete formulation is available Product UseFor Research Use Only Not for use in diagnostic procedures cGMP Manufacturing and Quality SystemGibco Trypsin is manufactured at a cGMP compliant facility located in Grand Island New York The facility is registered with the FDA as a medical device manufacturer and is certified to ISO 13485 standards
    https://www.bioz.com/result/trypsin edta solution/product/Thermo Fisher
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    trypsin edta solution - by Bioz Stars, 2021-04
    97/100 stars

    Images

    Related Articles

    Infection:

    Article Title: Human Rotavirus VP6-Specific Antibodies Mediate Intracellular Neutralization by Binding to a Quaternary Structure in the Transcriptional Pore
    Article Snippet: Cells MA-104 Clone 1 cells (ATCC CRL-2378.1) and Madin Darbin canine kidney (MDCK) cells (ATCC CCL-34) were grown in complete medium (CM) consisting of DMEM with 4.5% glucose (Mediatech) supplemented with 10% (v/v) fetal bovine serum (Invitrogen), 0.1 mM MEM non-essential amino acids (Invitrogen), 100 I.U./mL penicillin, 100 µg/mL streptomycin, 2 mM glutamine and 1 mM sodium pyruvate (all from Mediatech). .. Infection medium (IM), used when cells were inoculated with rotavirus and cultured, contained all of the above supplements except serum, and trypsin-EDTA (Invitrogen) was added to a final concentration of 1 µg/mL. .. A lineage of Caco-2 cells (a kind gift from Dr. Blaise Corthésy) derived by passage from a commercial cell line (HTB-37, American Type Culture Collection) were grown in CM supplemented with 0.1% transferrin (Sigma).

    Cell Culture:

    Article Title: Human Rotavirus VP6-Specific Antibodies Mediate Intracellular Neutralization by Binding to a Quaternary Structure in the Transcriptional Pore
    Article Snippet: Cells MA-104 Clone 1 cells (ATCC CRL-2378.1) and Madin Darbin canine kidney (MDCK) cells (ATCC CCL-34) were grown in complete medium (CM) consisting of DMEM with 4.5% glucose (Mediatech) supplemented with 10% (v/v) fetal bovine serum (Invitrogen), 0.1 mM MEM non-essential amino acids (Invitrogen), 100 I.U./mL penicillin, 100 µg/mL streptomycin, 2 mM glutamine and 1 mM sodium pyruvate (all from Mediatech). .. Infection medium (IM), used when cells were inoculated with rotavirus and cultured, contained all of the above supplements except serum, and trypsin-EDTA (Invitrogen) was added to a final concentration of 1 µg/mL. .. A lineage of Caco-2 cells (a kind gift from Dr. Blaise Corthésy) derived by passage from a commercial cell line (HTB-37, American Type Culture Collection) were grown in CM supplemented with 0.1% transferrin (Sigma).

    Concentration Assay:

    Article Title: Human Rotavirus VP6-Specific Antibodies Mediate Intracellular Neutralization by Binding to a Quaternary Structure in the Transcriptional Pore
    Article Snippet: Cells MA-104 Clone 1 cells (ATCC CRL-2378.1) and Madin Darbin canine kidney (MDCK) cells (ATCC CCL-34) were grown in complete medium (CM) consisting of DMEM with 4.5% glucose (Mediatech) supplemented with 10% (v/v) fetal bovine serum (Invitrogen), 0.1 mM MEM non-essential amino acids (Invitrogen), 100 I.U./mL penicillin, 100 µg/mL streptomycin, 2 mM glutamine and 1 mM sodium pyruvate (all from Mediatech). .. Infection medium (IM), used when cells were inoculated with rotavirus and cultured, contained all of the above supplements except serum, and trypsin-EDTA (Invitrogen) was added to a final concentration of 1 µg/mL. .. A lineage of Caco-2 cells (a kind gift from Dr. Blaise Corthésy) derived by passage from a commercial cell line (HTB-37, American Type Culture Collection) were grown in CM supplemented with 0.1% transferrin (Sigma).

    Modification:

    Article Title: Grb7-derived calmodulin-binding peptides inhibit proliferation, migration and invasiveness of tumor cells while they enhance attachment to the substrate
    Article Snippet: .. Dulbecco's modified Eagle's medium (DMEM), trypsin/EDTA, L-glutamine and FBS were obtained from Gibco; Anti-mouse IgG (whole molecule) HRP-conjugated secondary antibody (A9044), phenyl-Sepharose 6 (fast-flow), dansyl chloride, glutaraldehyde, N,N,N′,N′ -tetramethylethylenediamine, Triton X-100, Fast Green FC and Crystal Violet were purchased from Sigma-Aldrich; polyvinylidene difluoride (PVDF) membranes, the mouse monoclonal anti-phosphotyrosine antibody (clone 4G10, IgG2bκ isotype) made against phosphotyramine-KLH (keyhole limpet hemocyanin), fibronectin, dimethyl sulfoxide (DMSO), acrylamide and EGF were from Merck Millipore; W-7 and W-12 were obtained from Calbiochem or Abcam, and 5(6)-TAMRA was from Novabiochem®. .. The Diff-Quik staining kit was from Medion Diagnostics AG, bovine serum albumin (BSA) was from Nzytech and the enhanced chemiluminescence (ECL) kit was purchased from GE Healthcare-Amersham.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    Thermo Fisher trypsin edta
    Membrane binding of the key PNN component aggrecan is biochemically altered in <t>Ptprz1</t> KO and Tnr KO mice brains. Brain homogenates were treated with ChABC to remove the hyaluronan backbone of PNNs or chondroitinase in the presence of <t>EDTA</t> (ChABC EDTA) and centrifuged to obtain soluble release ( R ) and insoluble pellet ( P ) fractions. A , Western blotting image showing release of PNN marker aggrecan into soluble phase from brain homogenates of WT, Ptprz1 KO, and Tnr KO mice by ChABC treatment alone and ChABC EDTA treatment. The release of aggrecan into the soluble fraction required ChABC treatment in addition with EDTA in WT brain homogenates. Aggrecan was released more readily with just ChABC treatment in Ptprz1 KO and Tnr KO animals. B , quantification showing ratio of the soluble release fraction ( R ) to total aggrecan levels (soluble release (R) + insoluble pellet (P)) in WT, Ptprz1 KO, and Tnr KO mice. There was a statistically significant difference in the release of aggrecan among the three genotypes as determined by one-way ANOVA (F(2,7) = 14.94, p = 0.0030). A Tukey's post hoc test showed that aggrecan was released much more readily in Ptprz1 KO mice (42 ± 0.04%, p = 0.0340) as well as in Tnr KO mice (58 ± 13%, p = 0.0024) compared with WT mice (15 ± 9%) when treated with just ChABC. There was no significant difference in aggrecan release between Ptprz1 KO and Tnr KO brains. Treatment with ChABC alongside EDTA led to almost complete release of aggrecan into the soluble release fraction in all genotypes. The ratio of release to total in Ptprz1 KO, Tnr KO and WT mice was not significantly different among the genotypes in the ChABC with EDTA treatment group. B , bars in graphs represent percentage release ± S.D.
    Trypsin Edta, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/trypsin edta/product/Thermo Fisher
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    trypsin edta - by Bioz Stars, 2021-04
    97/100 stars
      Buy from Supplier

    Image Search Results


    Membrane binding of the key PNN component aggrecan is biochemically altered in Ptprz1 KO and Tnr KO mice brains. Brain homogenates were treated with ChABC to remove the hyaluronan backbone of PNNs or chondroitinase in the presence of EDTA (ChABC EDTA) and centrifuged to obtain soluble release ( R ) and insoluble pellet ( P ) fractions. A , Western blotting image showing release of PNN marker aggrecan into soluble phase from brain homogenates of WT, Ptprz1 KO, and Tnr KO mice by ChABC treatment alone and ChABC EDTA treatment. The release of aggrecan into the soluble fraction required ChABC treatment in addition with EDTA in WT brain homogenates. Aggrecan was released more readily with just ChABC treatment in Ptprz1 KO and Tnr KO animals. B , quantification showing ratio of the soluble release fraction ( R ) to total aggrecan levels (soluble release (R) + insoluble pellet (P)) in WT, Ptprz1 KO, and Tnr KO mice. There was a statistically significant difference in the release of aggrecan among the three genotypes as determined by one-way ANOVA (F(2,7) = 14.94, p = 0.0030). A Tukey's post hoc test showed that aggrecan was released much more readily in Ptprz1 KO mice (42 ± 0.04%, p = 0.0340) as well as in Tnr KO mice (58 ± 13%, p = 0.0024) compared with WT mice (15 ± 9%) when treated with just ChABC. There was no significant difference in aggrecan release between Ptprz1 KO and Tnr KO brains. Treatment with ChABC alongside EDTA led to almost complete release of aggrecan into the soluble release fraction in all genotypes. The ratio of release to total in Ptprz1 KO, Tnr KO and WT mice was not significantly different among the genotypes in the ChABC with EDTA treatment group. B , bars in graphs represent percentage release ± S.D.

    Journal: The Journal of Biological Chemistry

    Article Title: The protein tyrosine phosphatase RPTPζ/phosphacan is critical for perineuronal net structure

    doi: 10.1074/jbc.RA119.010830

    Figure Lengend Snippet: Membrane binding of the key PNN component aggrecan is biochemically altered in Ptprz1 KO and Tnr KO mice brains. Brain homogenates were treated with ChABC to remove the hyaluronan backbone of PNNs or chondroitinase in the presence of EDTA (ChABC EDTA) and centrifuged to obtain soluble release ( R ) and insoluble pellet ( P ) fractions. A , Western blotting image showing release of PNN marker aggrecan into soluble phase from brain homogenates of WT, Ptprz1 KO, and Tnr KO mice by ChABC treatment alone and ChABC EDTA treatment. The release of aggrecan into the soluble fraction required ChABC treatment in addition with EDTA in WT brain homogenates. Aggrecan was released more readily with just ChABC treatment in Ptprz1 KO and Tnr KO animals. B , quantification showing ratio of the soluble release fraction ( R ) to total aggrecan levels (soluble release (R) + insoluble pellet (P)) in WT, Ptprz1 KO, and Tnr KO mice. There was a statistically significant difference in the release of aggrecan among the three genotypes as determined by one-way ANOVA (F(2,7) = 14.94, p = 0.0030). A Tukey's post hoc test showed that aggrecan was released much more readily in Ptprz1 KO mice (42 ± 0.04%, p = 0.0340) as well as in Tnr KO mice (58 ± 13%, p = 0.0024) compared with WT mice (15 ± 9%) when treated with just ChABC. There was no significant difference in aggrecan release between Ptprz1 KO and Tnr KO brains. Treatment with ChABC alongside EDTA led to almost complete release of aggrecan into the soluble release fraction in all genotypes. The ratio of release to total in Ptprz1 KO, Tnr KO and WT mice was not significantly different among the genotypes in the ChABC with EDTA treatment group. B , bars in graphs represent percentage release ± S.D.

    Article Snippet: Briefly, cortices of embryonic day (E) 16 CD-1 WT or Ptprz1 KO embryos were removed and digested in 0.25% trypsin-EDTA (Thermo Fisher Scientific).

    Techniques: Binding Assay, Mouse Assay, Western Blot, Marker

    Signalling pathways in TL2i cells. ( a ) Phase-contrast microphotographs, AP activity and immunofluorescence labelling of OCT4, SSEA4 and TRA-1–60 in TL2i cells. ( b ) A colony-forming assay with TL2i-OS3–10 and TL2i-H9S3-2 cells (representative experiment). Cell clumps were plated in TL2i medium supplemented with pharmacological inhibitors of JAK2 (SD1029 at 10 μM), FGFR (SU5402 at 10 μM) and SMADs (SB431542 at 10 μM), and cultivated for 5 days. Upper panels: staining to reveal AP activity; bottom panels: histograms showing the percentage of undifferentiated, mixed and differentiated colonies. ( n =3; error bars indicates the mean±s.e.m.). ( c ) Histogram representation of the mRNA level (ΔCt) of pluripotency genes in TL2i-OS3–10 cells before and treatment with FGFR inhibitor SU5402 for 5 days after normalization to GAPDH (ΔCt=1). ( n =3, mean±s.d.). ( d ) Characteristics of TL2i-OS3–10 cells after propagation on Matrigel without MEF; AP, alkaline phosphatase activity. ( e ) Histograms showing the percentage of undifferentiated, mixed and differentiated colonies ( n =3; error bars indicate the mean±s.e.m.) in a colony-forming assay with TL2i-OS3–10 cells (representative experiment). Cell clumps were plated in a medium supplemented with pharmacological inhibitors of FGFR (SU5402 at 10 μM) and SMADs (SB431542 at 10 μM), and cultivated for 5 days with LIF+4′-OHT. ( f ) Histogram representation of the mRNA level (ΔCt) of LIFR , GP130 , JAK and STAT3 genes in TL2i-H9S3-2 cells, after normalization to GAPDH (ΔCt=1), then to TL-H9S3-2 (blue bars) and F-H9S3-2 cells (red bars). ( n =3, mean±s. d.). ( g ) Western blot analysis of STAT3 and STAT3-ER T2 expression in OSCAR, F-H9S3-2, TL-H9S3-2 and TL2i-H9S3-2 cells, analysed with antibodies to total STAT3, phospho-(Tyr705)-STAT3 and phospho-(Ser720)-STAT3. One representative experiment of three repeats is shown. ( h ) Phase-contrast microphotographs (PC) and immunofluorescence labelling of OCT4, NANOG, SSEA4 and TRA-1–81 in TL2i-OS3–10 cells after culturing in 2i/LIF medium without 4′-OHT for 30 passages. ( i ) Western blot analysis of STAT3 and STAT3-ER T2 expression in TL-OS3–10 cells and TL2i-OS3–10 cells (+/−4′-OHT), analysed with antibodies to total STAT3. One representative experiment of two repeats is shown. ( j ) Phase-contrast microphotographs (PC), AP detection and immunofluorescence labelling of OCT4, NANOG, TRA-1–81 and SSEA4 in TL2i-OS3–10 cells after culturing in N2B27+2i/LIF basal medium for eight passages. ( k ) Histogram representation of the cloning efficiency of F, TL and TL2i cells (OS3–10, H9S3–2 and H9S3–14 lines) after single-cell dissociation with 0.05% trypsin-EDTA and re-plating on feeders in the presence of 10 μM ROCK inhibitor Y-27632 for 24 h post dissociation. Tukey's test; n =3; error bars indicate the mean±s. e. Scale bar, 50 μm ( a , d , h , i ).

    Journal: Nature Communications

    Article Title: Reinforcement of STAT3 activity reprogrammes human embryonic stem cells to naive-like pluripotency

    doi: 10.1038/ncomms8095

    Figure Lengend Snippet: Signalling pathways in TL2i cells. ( a ) Phase-contrast microphotographs, AP activity and immunofluorescence labelling of OCT4, SSEA4 and TRA-1–60 in TL2i cells. ( b ) A colony-forming assay with TL2i-OS3–10 and TL2i-H9S3-2 cells (representative experiment). Cell clumps were plated in TL2i medium supplemented with pharmacological inhibitors of JAK2 (SD1029 at 10 μM), FGFR (SU5402 at 10 μM) and SMADs (SB431542 at 10 μM), and cultivated for 5 days. Upper panels: staining to reveal AP activity; bottom panels: histograms showing the percentage of undifferentiated, mixed and differentiated colonies. ( n =3; error bars indicates the mean±s.e.m.). ( c ) Histogram representation of the mRNA level (ΔCt) of pluripotency genes in TL2i-OS3–10 cells before and treatment with FGFR inhibitor SU5402 for 5 days after normalization to GAPDH (ΔCt=1). ( n =3, mean±s.d.). ( d ) Characteristics of TL2i-OS3–10 cells after propagation on Matrigel without MEF; AP, alkaline phosphatase activity. ( e ) Histograms showing the percentage of undifferentiated, mixed and differentiated colonies ( n =3; error bars indicate the mean±s.e.m.) in a colony-forming assay with TL2i-OS3–10 cells (representative experiment). Cell clumps were plated in a medium supplemented with pharmacological inhibitors of FGFR (SU5402 at 10 μM) and SMADs (SB431542 at 10 μM), and cultivated for 5 days with LIF+4′-OHT. ( f ) Histogram representation of the mRNA level (ΔCt) of LIFR , GP130 , JAK and STAT3 genes in TL2i-H9S3-2 cells, after normalization to GAPDH (ΔCt=1), then to TL-H9S3-2 (blue bars) and F-H9S3-2 cells (red bars). ( n =3, mean±s. d.). ( g ) Western blot analysis of STAT3 and STAT3-ER T2 expression in OSCAR, F-H9S3-2, TL-H9S3-2 and TL2i-H9S3-2 cells, analysed with antibodies to total STAT3, phospho-(Tyr705)-STAT3 and phospho-(Ser720)-STAT3. One representative experiment of three repeats is shown. ( h ) Phase-contrast microphotographs (PC) and immunofluorescence labelling of OCT4, NANOG, SSEA4 and TRA-1–81 in TL2i-OS3–10 cells after culturing in 2i/LIF medium without 4′-OHT for 30 passages. ( i ) Western blot analysis of STAT3 and STAT3-ER T2 expression in TL-OS3–10 cells and TL2i-OS3–10 cells (+/−4′-OHT), analysed with antibodies to total STAT3. One representative experiment of two repeats is shown. ( j ) Phase-contrast microphotographs (PC), AP detection and immunofluorescence labelling of OCT4, NANOG, TRA-1–81 and SSEA4 in TL2i-OS3–10 cells after culturing in N2B27+2i/LIF basal medium for eight passages. ( k ) Histogram representation of the cloning efficiency of F, TL and TL2i cells (OS3–10, H9S3–2 and H9S3–14 lines) after single-cell dissociation with 0.05% trypsin-EDTA and re-plating on feeders in the presence of 10 μM ROCK inhibitor Y-27632 for 24 h post dissociation. Tukey's test; n =3; error bars indicate the mean±s. e. Scale bar, 50 μm ( a , d , h , i ).

    Article Snippet: TL2i cells were regularly passaged by single-cell dissociation with 0.05% trypsin-EDTA (Gibco) every 4 days.

    Techniques: Activity Assay, Immunofluorescence, Staining, Western Blot, Expressing, Clone Assay

    Anti-rotaviral activity of RV6-26. (A) Inhibition of in vitro transcription: EDTA-activated DLP were incubated with 200 nM combining sites of different antibodies and mRNA was synthesized in vitro using selected components of the Riboprobe SP6 system (transcription was mediated by the viral RNA-dependent RNA polymerase not the SP6 DNA-dependent RNA polymerase). First-strand cDNA was synthesized by reverse transcription using a VP6-specific primer. Amplification of cDNA with VP6-specific primers was monitored in a real-time PCR using SYBR Green; the concentrations of RNA estimated from a standard curve constructed using reference RNA extracted from RRV are plotted. (B) Inhibition of rotavirus replication by IgA: polarized monolayers of Caco-2 cells grown on Transwell inserts were treated with polymeric IgA in the basal compartment and inoculated apically with trypsin-activated RRV (MOI = 5) at ambient temperature for 1 h and then cultured for 16 in medium containing trypsin. Amount of rotavirus in the inserts was titrated by inoculating MA104 cells and culturing for 16 h, followed by acetone-fixation and staining with anti-rotavirus polyclonal antibodies conjugated to either Alexa568 or IRDye 800. Detection was done either by scanning on Licor or by counting fluorescent foci.

    Journal: PLoS ONE

    Article Title: Human Rotavirus VP6-Specific Antibodies Mediate Intracellular Neutralization by Binding to a Quaternary Structure in the Transcriptional Pore

    doi: 10.1371/journal.pone.0061101

    Figure Lengend Snippet: Anti-rotaviral activity of RV6-26. (A) Inhibition of in vitro transcription: EDTA-activated DLP were incubated with 200 nM combining sites of different antibodies and mRNA was synthesized in vitro using selected components of the Riboprobe SP6 system (transcription was mediated by the viral RNA-dependent RNA polymerase not the SP6 DNA-dependent RNA polymerase). First-strand cDNA was synthesized by reverse transcription using a VP6-specific primer. Amplification of cDNA with VP6-specific primers was monitored in a real-time PCR using SYBR Green; the concentrations of RNA estimated from a standard curve constructed using reference RNA extracted from RRV are plotted. (B) Inhibition of rotavirus replication by IgA: polarized monolayers of Caco-2 cells grown on Transwell inserts were treated with polymeric IgA in the basal compartment and inoculated apically with trypsin-activated RRV (MOI = 5) at ambient temperature for 1 h and then cultured for 16 in medium containing trypsin. Amount of rotavirus in the inserts was titrated by inoculating MA104 cells and culturing for 16 h, followed by acetone-fixation and staining with anti-rotavirus polyclonal antibodies conjugated to either Alexa568 or IRDye 800. Detection was done either by scanning on Licor or by counting fluorescent foci.

    Article Snippet: Infection medium (IM), used when cells were inoculated with rotavirus and cultured, contained all of the above supplements except serum, and trypsin-EDTA (Invitrogen) was added to a final concentration of 1 µg/mL.

    Techniques: Activity Assay, Inhibition, In Vitro, Incubation, Synthesized, Amplification, Real-time Polymerase Chain Reaction, SYBR Green Assay, Construct, Cell Culture, Staining

    The effect of trypsinization on receptor expression. Lu1205 cells were detached from culture dishes by 0.05% trypsin-EDTA. Cells were incubated for 60 min in medium before being treated with trypsin for 5min. ICAM-1 (A) and α v β 3 (B) expressions

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: Sequential binding of ?v?3 and ICAM-1 determines fibrin-mediated melanoma capture and stable adhesion to CD11b/CD18 on neutrophils 1

    doi: 10.4049/jimmunol.1000494

    Figure Lengend Snippet: The effect of trypsinization on receptor expression. Lu1205 cells were detached from culture dishes by 0.05% trypsin-EDTA. Cells were incubated for 60 min in medium before being treated with trypsin for 5min. ICAM-1 (A) and α v β 3 (B) expressions

    Article Snippet: Prior to each experiment, Lu1205 cells were detached with 0.05% trypsin/EDTA (Invitrogen) and washed twice with fresh medium.

    Techniques: Expressing, Incubation